Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929063 | 0.90 | GPR84 (0.39) | MEN1KMT2AGPR84KDM4EMAPT | |
| SCHEMBL13868304 | 0.80 | GPR84 (0.54) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL29733041 | 0.80 | MEN1 (0.39) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL25484967 | 0.78 | GPR84 (0.44) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL22229709 | 0.78 | MEN1 (0.49) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL3921033 | 0.78 | MEN1 (0.37) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL3927270 | 0.78 | MEN1 (0.37) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL22229688 | 0.75 | GPR84 (0.38) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL3919802 | 0.74 | GPR84 (0.43) | MEN1KMT2AGPR84KDM4ERECQL | |
| SCHEMBL22256419 | 0.74 | MEN1 (0.36) | MEN1KMT2AGPR84KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517828-B2 | Chiral broensted acid catalyst for asymmetric synthesis and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1623971-A1 | ASYMMETRIC-SYNTHESIS CATALYST BASED ON CHIRAL BROENSTED ACID AND METHOD OF ASYMMETRIC SYNTHESIS WITH THE CATALYST | TOAGOSEI CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | LSS, COASY, FASN | MEN1 169/4885KMT2A 2039/4885CYP19A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.